Elevance Health, Inc. (ELV) Form 8-K — Jul 15, 2026
Elevance Health reported second quarter 2026 operating revenue of $49.8 billion, an increase of 0.8% year-over-year, with diluted EPS of $6.71 and adjusted diluted EPS of $7.45. The company exceeded its outlook, raising full-year 2026 adjusted diluted EPS guidance to at least $27.00 and operating cash flow guidance to at least $6.0 billion, supported by favorable benefit expense performance.
Key figures
- Eps
- 6.71
- Revenue
- 49.8
- Guidance
- FY 2026 diluted EPS at least $20.10; adjusted diluted EPS at least $27.00
- Revenue Yoy
- 0.8
- Cash Position
- 2.1
- Adjusted EPS
- 7.45
- Dividend Per Share
- 1.72
- Repurchase Amount
- 234
- Medical Membership
- 44.9
- Operating Cash Flow
- 1.9
- Shares Repurchased
- 0.7
- Benefit Expense Ratio
- 89.7%
- Remaining Repurchase Authorization
- 5.3
Price after filing
1 day: 0.0%7 days: -8.5%30 days: -6.3%
Close on the filing date to close N calendar days later (from $425.17). Historical, not a forecast.
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.